SFX by Ex Libris Inc.

Title:	p53 and treatment of bladder cancer
Source:	Nature [0028-0836] Cote, Richard yr:1997

Basic

Full text

Full text available via Nature

Year:

Volume:

Issue:

Start Page:

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	"Conformational Heterogeneity and Frustration of the Tumor Suppressor p53 as Tuned by Punctual Mutations." International journal of molecular sciences. 23.20: 12636-.
description	2.	Chung, Seung W. "Metronomic oral doxorubicin in combination of Chk1 inhibitor MK-8776 for p53-deficient breast cancer treatment." Biomaterials 182 (2018): 35-43.
description	3.	Duffy, Michael J. "Mutant p53 as a target for cancer treatment." European journal of cancer. 83: 258-265.
description	4.	CHOI, W. "Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy." Cancer cell 25.2 (2014): 152-165.
description	5.	Ryan, C W. "Gemcitabine in the treatment of bladder cancer." Expert opinion on pharmacotherapy 1.3 (2000): 547-553.
description	6.	HURST, C. "Molecular Subtyping of Invasive Bladder Cancer: Time to Divide and Rule?" Cancer cell 25.2 (2014): 135-136.
description	7.	Viktorsson, K. "The role of p53 in treatment responses of lung cancer." Biochemical and biophysical research communications 331.3 (2005): 868-880.
description	8.	Xue, Y. "Intratumour heterogeneity of p53 expression; causes and consequences." The Journal of Pathology 249.3 (2019): 274-285.
description	9.	"Hypermethylation of FOXA1 and allelic loss of PTEN drive squamous differentiation and promote heterogeneity in bladder cancer." Oncogene. 39.6: 1302-1317.
description	10.	Kotler, E. "A Systematic p53 Mutation Library Links Differential Functional Impact to Cancer Mutation Pattern and Evolutionary Conservation." Molecular cell 71.1 (2018): 178-4294967295.
description	11.	Matsuda, M. "Tumor heterogeneity in small hepatocellular carcinoma: analysis of tumor cell proliferation, expression and mutation of p53 AND beta-catenin." International journal of cancer 93.4 (2001): 468-74.
description	12.	Damrauer, Jeffrey S. "Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology." Proceedings of the National Academy of Sciences of the United States of America 111.8 (2014): 3110-3115.
description	13.	Witjes, Eva A. "EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2013 Guidelines." European urology 65.4 (2013): 778-792.
description	14.	Shariat, S F. "Prognostic value of P53 nuclear accumulation and histopathologic features in T1 transitional cell carcinoma of the urinary bladder." Urology 56.5 (2000): 735-740.
description	15.	LaRusch, Gretchen A A. "Nutlin3 blocks vascular endothelial growth factor induction by preventing the interaction between hypoxia inducible factor 1alpha and Hdm2." Cancer research 67.2 (2007): 450-4.
description	16.	Yao, P M M. "Free cholesterol loading of macrophages induces apoptosis involving the fas pathway." The Journal of biological chemistry 275.31 (2000): 23807-76.
description	17.	expertopinion@literatumonline.com (Fadi El Karak e, F. "Gemcitabine in bladder cancer." Expert Opinion on Pharmacotherapy 8.18 (2007): 3251-6.
description	18.	Loeb, L A A. "Microsatellite instability: marker of a mutator phenotype in cancer." Cancer research 55.23 (1994): 5059-63.
description	19.	Bennett, W P P. "Molecular epidemiology of human cancer risk: gene-environment interactions and p53 mutation spectrum in human lung cancer." The Journal of pathology 187.1 (1998): 8-18.
description	20.	Sonpavde, G. "Activity of CEP-9722, a poly (ADP-ribose) polymerase inhibitor, in urothelial carcinoma correlates inversely with homologous recombination repair response to DNA damage." Anti-cancer drugs 25.8 (2014): 878-886.